Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses

BACKGROUND: Candidate human papillomavirus (HPV) vaccines have demonstrated almost 90%-100% efficacy in preventing persistent, type-specific HPV infection over 18 mo in clinical trials. If these vaccines go on to demonstrate prevention of precancerous lesions in phase III clinical trials, they will...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnabas, Ruanne V, Laukkanen, Päivi, Koskela, Pentti, Kontula, Osmo, Lehtinen, Matti, Garnett, Geoff P
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1434486/
https://www.ncbi.nlm.nih.gov/pubmed/16573364
http://dx.doi.org/10.1371/journal.pmed.0030138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1434486/
https://www.ncbi.nlm.nih.gov/pubmed/16573364
http://dx.doi.org/10.1371/journal.pmed.0030138

Ejemplares similares